J&J Deal Watch: Johnson & Johnson agreed to pay about $5.5B to settle most remaining talc-related ovarian cancer claims, covering roughly 76,000 cases, with payments expected to start in 2027. Biotech M&A: J&J also struck a collaboration with Sail Biomedicines for in vivo CAR-T work and took an exclusive option to buy the New Jersey biotech for $2.58B. Healthcare Fraud: Federal prosecutors charged the founder of a Princeton-area eye care group, alleging an 8-year Medicare scheme involving tests that were allegedly never reviewed and unnecessary for surgery decisions. Corporate Finance: Bristol Myers Squibb raised its 2026 outlook after strong Q2 results, led by Eliquis and newer drugs. Real Estate: JLL arranged $15.35M financing for a Princeton office building, highlighting continued tenant demand and recent upgrades. Nuclear Decommissioning: The US NRC approved Holtec’s Oyster Creek license termination plan, mapping the final phase of decommissioning and restoration. Public Markets: Jersey Mike’s is set to go public at about a $7B valuation, with Blackstone’s employee-ownership approach in the spotlight. Tech & Privacy: A federal appeals court revived an antitrust case accusing major NJ casino operators of using AI pricing tools to inflate hotel rates. Energy/Defense: Ocean Power Technologies delivered a WAM-V maritime drone to Stevens Institute of Technology. Consumer/Compliance: Lidl issued a voluntary recall of shortbread cookies sold in NJ due to undeclared allergens. Local Economy: U-Haul’s migration data shows New Jersey appears among top destinations for some generations leaving the Boston area.